Get started

Editas

EDIT Editas medicine ready to break outBeen in this for a little while now since the change in market structure and added a few times to this position so not the best avg weighted entry but still well in profit. Classic sweep of lows and change in market structure has me excited on this position and more recently over the last month with the gap up above the previous short term high and now the ascending triangle forming showing the bulls still buying up and testing that resistance. The resistance may be strong but we have had a few cracks at it already and eventually I expect this level to break and to see another descent impulse move. Bullish on EDIT for now, momentum still on our side.
NASDAQ:EDITLong
by DeNomics
1
EDIT - EDITAS Genetics time to accumulate and play bounceHello all, Notice MACD, RSI and 50 day MA trends for EDIT. I am planning to accumulate calls this week and some last week to play the bounce signaled by RSI and MACD into the JPM healthcare conference on the 15th where these biotechs present promising results and play pop. Plus biotech is a risky defensive bet - mutually exclusive of Iran - these biotechs are still getting bought out and FDA is approving new drugs like candy.
NASDAQ:EDITLong
by ketokat
Investing In Genomics Anyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment opportunities and ideas all over the world. Start with what you know and what you are involved in, in your day to day life’’. Following this advice, I will share what I think is a potentially fantastic opportunity for readers interested in investing in healthcare. This opportunity lies in CRISPR. Looking back in recent history, it took over 13 years and an immense amount of computing power to map out the human genome. The process started in 2001 and cost 2.7 billion USD, 12 years later in 2012 CRISPR based genome-editing was birthed. In 2013 the cost to sequence a human genome has dropped from 2.7billion USD to 1000 USD. This deflationary trend is projected to continue into the 2020s and 2030s thus implying human gene sequencing will get cheaper and more affordable over time. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome-editing platform that dares to address the most salient health issues. read more at www.patreon.com NASDAQ:CRSP Many Thanks. R.M.D
NASDAQ:CRSP
by couragepharm
NTLA sitting at 17.28 resistance, will it break thru or to 15s?NTLA has been flying through resistance levels from oversold conditions and looks like it's testing 17.28 resistance to establish it as support. If it closes above, likely going higher - if it rejects off of 17.28 then likely retest of high 15s before re-testing 17s. Apart from ongoing patent battles, this company was hit by a scientific paper that made unfounded claims against their gene editing tech CRSPR, which prompted a panic sell. Yet another paper discrediting the previous negative article was released today, which explains the ~6% jump. This is a super undervalued company with no debt. Either way, I sold some calls against part of my holding since they filed forms which suggest they may be planning a secondary. Waiting for a nice red day to sell more puts. Buy and hold long with co-CRSPR-patent holders EDIT & CRSP.
NASDAQ:NTLALong
by heidib
EDIT off the bounce on low volume.Nice support level at $20 Filled Gap up and Gap down. If decent trading volume, long term investors or proponents to CAS-9 research will buy in at these support levels. CRISPR got upgraded. EDITAS holds patents that relate to the use of CRISPR-Cas9 in the cells of humans and other eukaryotes, while the UC Berkeley, Crispr, patents cover use of the gene-editing approach more generally. Licensing plays from one company to the other. No profit in the near term. Bump in stock off Crispr viral news.
NASDAQ:EDITLong
by tonyyubc